Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

Transgene S.A.. (4/10/17). "Press Release: Transgene Announces Upcoming Investor Meetings and R&D Day". Strasbourg.

Region Region Amsterdam
  Country Netherlands
Organisations Organisation Transgene S.A. (Euronext: TNG)
  Group Mérieux (Group)
  Organisation 2 Kempen & Co. N.V.
  Group Van Lanschot (Group)
Products Product Kempen Life Sciences Conference 2017 Amsterdam
  Product 2 TG4010 (MVA-MUC1-IL2) (Transgene)
Index terms Index term Mérieux–Van Lanschot: investor conference, 201704 supply service Transgene SA presents at Kempen Life Sciences Conference
  Index term 2 Mérieux–Kepler Chevreux: investor conference, 201706 supply service Transgene SA presents at Kepler Biotech Days 2017 in Paris
Persons Person Larguier, Lucie (Mérieux 201704 Director CorpComm + IR at Transgene before Citigate Dewe Rogerson Paris)
  Person 2 Perrier, Marine (Huntsworth 201701 at Citigate Dewe Rogerson)
     


Transgene today announced that management will participate in the upcoming investor events set out below.

• Kempen 10th Life Sciences Conference: April 19, 2017 - Amsterdam, Netherlands

• Kepler Biotech Days: June 9, 2017 - Paris, France


Transgene will host a “R&D Day”, on June 22, 2017 in Paris, France. The event which will be conducted in English will feature presentations from several leading international scientists and clinicians.

Next scheduled financial communication
1st quarter 2017 business update
April 25, 2017 after market close


Contacts

Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

Media contacts: Citigate Dewe Rogerson
David Dible / Marine Perrier
+ 44 (0)20 7638 9571
transgene@citigatedr.co.uk


About Transgene

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The Company has several other programs in clinical and preclinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at www.transgene.fr.

Follow us on Twitter: @TransgeneSA

   
Record changed: 2017-07-02

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Mérieux (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px